Albireo to Report Q4 and Year-End 2021 Financial Results on March 1
Albireo Pharma (Nasdaq: ALBO) will host a conference call and live audio webcast on March 1, 2022, at 10:00 a.m. ET to share a business update and review the financial results for Q4 and the year ended December 31, 2021. The company is known for developing novel bile acid modulators targeting rare liver diseases, with its lead product, Bylvay, set to treat pruritus linked to progressive familial intrahepatic cholestasis (PFIC). The conference call can be accessed via phone or a webcast available on Albireo's investor relations page.
- Bylvay approved by U.S. FDA for PFIC treatment.
- Phase 3 trials underway for other rare pediatric liver diseases.
- European approval for Bylvay with NHS recommendation in the UK.
- None.
— Conference call and webcast to be held at 10:00 a.m. ET —
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on March 1, 2022, to provide a business update and review the company’s financial results for the fourth quarter and year ended December 31, 2021.
To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13727211. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that participants register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC with pricing listing in Germany and guidance from the National Institute for Health and Care Excellence (NICE) recommending Bylvay for use in the National Health Service in the England, Wales and Northern Ireland UK. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2019 and 2020 Best Places to Work in Massachusetts. For more information on Albireo, please visit www.albireopharma.com.
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
What is the date of the Albireo Pharma conference call?
How can I access the Albireo Pharma conference call?
What topics will Albireo Pharma cover in the conference call?
What is Bylvay and its significance for Albireo Pharma?
What are the ongoing clinical studies for Albireo Pharma?
